info@seagull-health.com
SeagullHealth
语言:
search
How well does Dacomitinib(Vizimpro) work?
VIZIMPRO demonstrated improved progression-free survival in patients with EGFR-positive metastatic NSCLC compared to gefitinib.
Clinical Effectiveness
In a clinical trial, patients treated with VIZIMPRO showed a median progression-free survival of 14.7 months, compared to 9.2 months for those on gefitinib. The overall response rate was 75%, with a median duration of response of 14.8 months, supporting its efficacy as a first-line treatment option.
Related Columns
Dacomitinib(Vizimpro)
A kinase inhibitor indicated for the first-line treatment of metastatic...
WeChat Scan
Free Inquiry
Free Inquiry
Related articles
共 0 条
- 1
Departments
New Articles
New Drugs
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
Contact Us
- mailbox：info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved